The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
How I treat secondary CNS involvement by aggressive lymphomas
Alderuccio, J. P., Nayak, L., & Cwynarski, K. (2023) · Blood · doi:10.1182/blood.2023020168 · Cited by 35
Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I., Gabrielli, G., Nasta, S. D., Porazzi, P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011492 · Cited by 38
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault, M. J., Graham, C., Berger, T. R., Ritchey, J., Horick, N., El-Jawahri, A. R., Scarfò, I., Schmidts, A., Haradhvala, N. J., Wehrli, M., et al. (2024) · Blood · doi:10.1182/blood.2024024104 · Cited by 37
Noncanonical and mortality-defining toxicities of CAR T cell therapy
Rejeski, K., Hill, J. A., Dahiya, S., & Jain, M. D. (2025) · Nature Medicine · doi:10.1038/s41591-025-03813-5 · Cited by 42
Advances in Management for Older Adults With Hematologic Malignancies
Rosko, A. E., Córdoba, R., Abel, G. A., Artz, A. S., Loh, K. P., & Klepin, H. D. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00242 · Cited by 35
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Yin, Z., Zhang, Y., & Wang, X. (2021) · Biomarker Research · doi:10.1186/s40364-021-00309-5 · Cited by 36
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 36
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas
Etrych, T., Braunová, A., Zogala, D., Lambert, L., Renešová, N., & Klener, P. (2022) · Cancers · doi:10.3390/cancers14030626 · Cited by 38
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
Mandriani, B., Pellè, E., Mannavola, F., Palazzo, A. J., Marsano, R. M., Ingravallo, G., Cazzato, G., Ramello, M. C., Porta, C., Strosberg, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004854 · Cited by 41
What is the future of immunotherapy in multiple myeloma?
Rasche, L., Hudecek, M., & Einsele, H. (2020) · Blood · doi:10.1182/blood.2019004176 · Cited by 35
Metelo, A. M., Jóźwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., Inam, S., Dunlop, A. S., Sanchez, K., Cuthill, K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0157 · Cited by 35
Ho, M., Zanwar, S., & Paludo, J. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14074 · Cited by 34
Bachiller, M., Barceló-Genestar, N., Rodríguez-García, A., Alserawan, L., Dobaño‐López, C., Giménez-Alejandre, M., Castellsagué, J., Colell, S., Otero-Mateo, M., Antoñana-Vildosola, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.028 · Cited by 35
Recent advances in universal chimeric antigen receptor T cell therapy
Jiang, N., Yang, Z., Miao, H., Xing, S., Wang, S., & Li, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01737-8 · Cited by 41
Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I. C., Räty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P. L., Nilsson‐Ehle, H., Bentzen, H., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000510 · Cited by 34
CAR T cell therapy in solid tumors: a short review
Umut, Ö., Gottschlich, A., Endres, S., & Kobold, S. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00703-7 · Cited by 37
Cardiovascular Toxicities of CAR T-cell Therapy
Patel, N. P., Doukas, P. G., Gordon, L. I., & Akhter, N. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01068-0 · Cited by 34
Taromi, S., Firat, E., Simonis, A., Braun, L. M., Apostolova, P., Elze, M., Passlick, B., Schumacher, A., Lagies, S., Frey, A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215697 · Cited by 34
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
Silva, D. D., Ferguson, L., Chin, G. H., Smith, B. E., Apathy, R., Roth, T. L., Blaeschke, F., Kudla, M., Marson, A., Ingolia, N. T., et al. (2021) · eLife · doi:10.7554/elife.74272 · Cited by 32
Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss
Furqan, F., & Shah, N. N. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-024719 · Cited by 35
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors
Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 34
Emole, J., Lawal, O., Lupak, O., Dias, A., Shune, L. O., & Yusuf, K. K. (2022) · Cancer Medicine · doi:10.1002/cam4.4797 · Cited by 33
Fugere, T., Baltz, A., Mukherjee, A., Gaddam, M., Varma, A., Veeraputhiran, M. K., & Sanchez, C. G. (2023) · Cancers · doi:10.3390/cancers15215149 · Cited by 37
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez, B., Rivas-Pardo, B., del Moral, M. G., Subiza, J. L., & Martı́nez-Naves, E. (2024) · Cells · doi:10.3390/cells13090725 · Cited by 34
Haydu, J. E., & Abramson, J. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2021004535 · Cited by 35
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38
CD19-directed CAR T-cell therapy in B-cell NHL
Kersten, M. J., Spanjaart, A. M., & Thiéblemont, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000668 · Cited by 33
Self-citationA single-chain antibody generation system yielding CAR-T cells with superior antitumor function
Ochi, T., Maruta, M., Tanimoto, K., Kondo, F., Yamamoto, T., Kurata, M., Fujiwara, H., Masumoto, J., Takenaka, K., & Yasukawa, M. (2021) · Communications Biology · doi:10.1038/s42003-021-01791-1 · Cited by 33
CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
Taneja, A., & Jain, T. (2021) · eJHaem · doi:10.1002/jha2.350 · Cited by 33
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model
Wang, Y., Buck, A., Grimaud, M., Culhane, A. C., Kodangattil, S. R., Razimbaud, C., Bonal, D. M., Nguyen, Q., Zhu, Z., Wei, K. S., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.019 · Cited by 34
Michaux, A., Mauën, S., Breman, E., Dheur, M.-S., Twyffels, L., Saerens, L., Jacques-Hespel, C., Gauthy, E., Agaugué, S., Gilham, D., et al. (2022) · Journal of immunotherapy · doi:10.1097/cji.0000000000000413 · Cited by 30
Ababneh, H., Abramson, J. S., Johnson, P. C., & Patel, C. G. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.08.007 · Cited by 34
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Beyar‐Katz, O., Perry, C., On, Y. B., Amit, O., Gutwein, O., Wolach, O., Kedar, R., Pikovsky, O., Avivi, I. M., Gold, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04889-6 · Cited by 32
Yuti, P., Sawasdee, N., Natungnuy, K., Rujirachaivej, P., Luangwattananun, P., Sujjitjoon, J., & Yenchitsomanus, P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115691 · Cited by 36
Storci, G., Felice, F. D., Ricci, F., Santi, S., Messelodi, D., Bertuccio, S. N., Laprovitera, N., Dicataldo, M., Rossini, L., Matteis, S. D., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173096 · Cited by 32
Κωστόπουλος, Ν., Costabile, F., Krimitza, E., Beghi, S., Goia, D., Perales-Linares, R. F., Thyphronitis, G., Lariviere, M. J., Chong, E. A., Schuster, S. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012599 · Cited by 34
Yang, Y., Peng, H., Wang, J., & Li, F. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00573-9 · Cited by 37
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D. P., Hosszu, K., Cancio, M., Jakubowski, A. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015157 · Cited by 34
In vivo CART cell imaging: Paving the way for success in CART cell therapy
Sakemura, R. L., Can, İ., Siegler, E. L., & Kenderian, S. S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.003 · Cited by 33
Smirnov, S., Petukhov, A., Levchuk, K., Kulemzin, S. V., Staliarova, A., Lepik, K. V., Shuvalov, O. Y., Zaritskey, A. Y., Daks, A. A., & Fedorova, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780145 · Cited by 34
Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E. D., Luppi, M., & Platzbecker, U. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000802 · Cited by 34
Rana, P. S., Soler, D. C., Kort, J., & Driscoll, J. J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1059715 · Cited by 34
Taking T-Cell Oncotherapy Off-the-Shelf
Mo, F., Mamonkin, M., Brenner, M. K., & Heslop, H. E. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.01.004 · Cited by 31
Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
Schmidt, D., Ebrahimabadi, S., Gomes, K. R. D. S., Aguiar, G. D. M., Tirapelle, M. C., Silvestre, R. N., de Azevedo, J. T. C., Covas, D. T., & Picanço‐Castro, V. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac003 · Cited by 34
Mody, H. R., Ogasawara, K., Zhu, X., Miles, D., Shastri, P. N., Gokemeijer, J., Liao, M. Z., Kasichayanula, S., Yang, T., Chemuturi, N. V., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2986 · Cited by 34
Ramos, A., Koch, C. E., Liu-Lupo, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Eidell, K. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43790-2 · Cited by 32
CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy
Guffroy, A., Jacquel, L., Guffroy, B., & Martin, T. (2024) · Joint Bone Spine · doi:10.1016/j.jbspin.2024.105702 · Cited by 31
Engineering CAR-T therapies for autoimmune disease and beyond
English, E. P., Swingler, R. N., Patwa, S., Tosun, M., Howard, J. F., Miljković, M. D., & Jewell, C. M. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado2084 · Cited by 35
Filgrastim associations with CAR T‐cell therapy
Gaut, D. L., Tang, K., Sim, M., Duong, T., Young, P. A., & Sasine, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33356 · Cited by 34
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials
Chintala, N. K., Restle, D. J., Quach, H. T., Saini, J. K., Bellis, R. Y., Offin, M. D., Beattie, J., & Adusumilli, P. S. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.004 · Cited by 31
Clinical translation of immunomodulatory therapeutics
Nash, A., Aghlara-Fotovat, S., Hernández, A., Scull, C. M., & Omid Veiseh, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113896 · Cited by 31
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
Wang, H., Wang, L., Li, Y., Li, G., Zhang, X., Jiang, D., Zhang, Y.-T. Y., Liu, L., Chu, Y., & Xu, G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02151-z · Cited by 31
Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
Sawalha, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121345 · Cited by 31
Buechner, J., Caruana, I., Künkele, A., Rives, S., Vettenranta, K. K., Bader, P., Peters, C., Baruchel, A., & Calkoen, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784024 · Cited by 32
Drougkas, K., Karampinos, K. I., Karavolias, I., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Trontzas, I. P., & Kotteas, E. A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04547-4 · Cited by 30
Incidence of MACE in Patients Treated With CAR-T Cell Therapy
Lefebvre, B., Kang, Y., Vakilpour, A., Onoue, T., Frey, N. V., Brahmbhatt, P., Huang, B. Z., Oladuja, K., Koropeckyj-Cox, D., Wiredu, C., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.07.009 · Cited by 29
Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases
Lyu, X., Gupta, L., Tholouli, E., & Chinoy, H. (2023) · Rheumatology · doi:10.1093/rheumatology/kead616 · Cited by 34
Hamilton, M. P., Craig, E. M., Sanchez, C. G., Mina, A. A., Tamaresis, J. S., Kirmani, N., Ehlinger, Z. J., Syal, S., Good, Z., Sworder, B. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012637 · Cited by 30
Self-citationChen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 32
CAR-armored-cell therapy in solid tumor treatment
Liu, Y., Xiao, L., Yang, M., Chen, X., Liu, H., Wang, Q., Guo, M., & Luo, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05903-3 · Cited by 32
Wang, Z., & Kelley, S. O. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01315-2 · Cited by 33
Schepisi, G., Casadei, C., Toma, I., Poti, G., Iaia, M. L., Farolfi, A., Conteduca, V., Lolli, C., Ravaglia, G., Brighi, N., et al. (2021) · Cancers · doi:10.3390/cancers13040840 · Cited by 31
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Nezhad, M. S., Yazdanifar, M., Abdollahpour‐Alitappeh, M., Sattari, A., Seifalian, A. M., & Bagheri, N. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27882 · Cited by 30
Das, S., & Dasari, A. N. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018047 · Cited by 30
Wang, S., Sellner, L., Wang, L., Sauer, T., Neuber, B., Gong, W., Stock, S., Ni, M., Yao, H., Kleist, C., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8121 · Cited by 30
Lee, D. C., Jordan, A. I., Menges, M. A., Lazaryan, A., Nishihori, T., Gaballa, S. R., Shah, B. D., Pinilla-Ibarz, J. A., Baluch, A., Klinkova, O. V., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.011 · Cited by 30
Self-citationSwitchable targeting of solid tumors by BsCAR T cells
Stepanov, A. V., Kalinin, R. S., Shipunova, V. O., Zhang, D., Xie, J., Rubtsov, Y. P., Ukrainskaya, V. M., Schulga, A. A., Коновалова, Е. В., Volkov, D. V., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210562119 · Cited by 29
Chimeric antigen receptor T-cell therapy for T-ALL and AML
Wei, W., Yang, D. F., Chen, X., Liang, D., Zou, L., & Zhao, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.967754 · Cited by 30
Mak, J. W. Y., Law, A. W. H., Law, K. W. T., Ho, R., Cheung, C. K. M., & Law, M. F. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i33.4942 · Cited by 34
Luo, W., Li, C., Wu, J., Tang, L., Wang, X., Zhang, Y., Wu, Z., Huang, Z., Xu, J., Kang, Y. J., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.03.005 · Cited by 31
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
Sloan, S. L., Brown-Burke, F., Long, M., Weigel, C., Koirala, S., Chung, J.-H., Pray, B. A., Villagomez, L., Hinterschied, C., Sircar, A., et al. (2023) · Blood · doi:10.1182/blood.2022019419 · Cited by 31
O'Reilly, M. A., Wilson, W., Burns, D., Kühnl, A., Seymour, F., Uttenthal, B., Besley, C., Alajangi, R., Creasey, T., Paneesha, S., et al. (2024) · HemaSphere · doi:10.1002/hem3.87 · Cited by 29
Chen, Z., Ren, A., Li, Y., Shu, J., Wu, J., Huang, H., Wang, J., Hu, Y., & Mei, H. (2025) · British Journal of Haematology · doi:10.1111/bjh.19988 · Cited by 29
Stock, S., Bücklein, V., Blumenberg, V., Magno, G., Emhardt, A., Holzem, A. M. E., dos Santos, D. M. C., Schmidt, C., Grießhammer, S., Frölich, L., et al. (2025) · HemaSphere · doi:10.1002/hem3.70062 · Cited by 29
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
Stahl, D. J., Gödel, P., Balke‐Want, H., Gholamipoorfard, R., Segbers, P., Tetenborg, L., Koker, M., Dörr, J., Gregor, L., Bachurski, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.013 · Cited by 37
Advances in chimeric antigen receptor T cells
Beyar‐Katz, O., & Gill, S. I. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000614 · Cited by 29
Sawalha, Y., Goyal, S., Switchenko, J. M., Romancik, J. T., Kamdar, M. K., Greenwell, I. B., Hess, B. T., Isaac, K. M., Portell, C. A., Garcia, A. M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008916 · Cited by 29
Self-citationCamilli, M., Maggio, L., Tinti, L., Lamendola, P., Lanza, G. A., Crea, F., & Lombardo, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1090103 · Cited by 29
Enabling CAR T ‐cell therapies for HIV ‐positive lymphoma patients – A call for action
Hattenhauer, T., Mispelbaum, R., Hentrich, M., Boesecke, C., & Monin, M. B. (2023) · HIV Medicine · doi:10.1111/hiv.13514 · Cited by 29
Katiyar, V., Chesney, J. A., & Kloecker, G. H. (2023) · Cancers · doi:10.3390/cancers15143733 · Cited by 32
Oluwole, O. O., Dholaria, B., Knight, T. E., Jain, T., Locke, F. L., Ramsdell, L. A., Nikiforow, S., Hashmi, H., Mooney, K., Bhaskar, S., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.11.008 · Cited by 29
Self-citationLeukapheresis for CAR-T cell production and therapy
Pessach, I., & Nagler, A. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103828 · Cited by 32
Nanomaterials Boost CAR‐T Therapy for Solid Tumors
Long, J., Wang, Y., Jiang, X., Ge, J., Chen, M., Zheng, B., Wang, R., Wang, M., Xu, M., Qi, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304615 · Cited by 28
Self-citationDawn of CAR-T cell therapy in autoimmune diseases
Liu, Y., Dong, M., Chu, Y., Zhou, L., You, Y., Pang, X., Yang, S., Zhang, L., Chen, L., Zhu, L., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003111 · Cited by 30
Thavorn, K., Thompson, E. R., Kumar, S., Heiskanen, A., Agarwal, A., Atkins, H. L., Shorr, R., Hawrysh, T., Chan, K., Presseau, J., et al. (2024) · Value in Health · doi:10.1016/j.jval.2024.04.004 · Cited by 28
Locke, F. L., Siddiqi, T., Jacobson, C. A., Ghobadi, A., Ahmed, S., Miklos, D. B., Perales, M., Munoz, J. L., Fingrut, W. B., Pennisi, M., et al. (2024) · Blood · doi:10.1182/blood.2023023447 · Cited by 28
Self-citationFurqan, F., Bhatlapenumarthi, V., Dhakal, B., Fenske, T. S., Farrukh, F., Longo, W., Akhtar, O. S., D’Souza, A., Pasquini, M. C., Murthy, G. S. G., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013239 · Cited by 28
Marangon, M., Visco, C., Barbui, A. M., Chiappella, A., Fabbri, A., Ferrero, S., Galimberti, S., Luminari, S., Musuraca, G., Re, A., et al. (2021) · Cancers · doi:10.3390/cancers13020291 · Cited by 28
In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology
Lechermann, L. M., Lau, D., Attili, B. N. N. R., Aloj, L., & Gallagher, F. A. (2021) · Cancers · doi:10.3390/cancers13164042 · Cited by 27
Advances in mRNA-based drug discovery in cancer immunotherapy
Trani, C. A. D., Fernández-Sendin, M., Cirella, A., Segués, A., Olivera, I., Bolaños, E., Melero, I., & Berraondo, P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1978972 · Cited by 28
Lu, Y., Li, L., Du, J., Chen, J., Xu, X., Yang, X., Ding, C., & Mao, C. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c17498 · Cited by 28
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Burkart, M., & Karmali, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030376 · Cited by 28
Xiao, X., Wang, Y., Zou, Z., Yang, Y., Wang, X., Xin, X., Tu, S., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954235 · Cited by 28
Winkelmann, M., Blumenberg, V., Rejeski, K., Bücklein, V., Ruzicka, M., Unterrainer, M., Schmidt, C., Dekorsy, F. J., Bartenstein, P., Ricke, J., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06075-2 · Cited by 27
Butt, O. H., Zhou, A. Y., Ances, B. M., DiPersio, J. F., & Ghobadi, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1110647 · Cited by 28
Li, R., & Cao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194020 · Cited by 28
Teoh, J. J., & Brown, L. F. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.013 · Cited by 29
Leung, I., Templeton, M. L., Lo, Y., Rajan, A., Stull, S. M., Garrison, S. M., Salter, A. I., Smythe, K. S., Correnti, C., Srivastava, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008559 · Cited by 28
Liu, W., Liu, W., Zou, H., Chen, L. P., Huang, W., Lv, R., Xu, Y., Liu, H., Shi, Y., Wang, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008857 · Cited by 27
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
